Get started
Author

Svetlana Balandraud

Observed name: S. Balandraud
Institution: Enterome (France)
ORCID: 0000-0002-2094-8451
Observed ORCID: 0000-0002-2094-8451
OpenAlex ID: A5040374787
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
2020 · Reuben Benjamin, Charlotte Graham, et al. · The Lancet · 392
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
2022 · Reuben Benjamin, Nitin Jain, et al. · The Lancet Haematology · 159
Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
2018 · Reuben Benjamin, Charlotte Graham, et al. · Blood · 91
Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
2017 · Charlotte Graham, Deborah Yallop, et al. · Blood · 30
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
2022 · Sandra Dupouy, Ibtissam Marchiq, et al. · Cancer Research Communications · 23
PDF
301 First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors
2015 · A. Azaro, J. Rodon, et al. · European Journal of Cancer · 4
162P EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)
2024 · R. Cohen, M.E. Elez Fernandez, et al. · Immuno-Oncology Technology · 2
PDF
125O First-in-human study of oral S 49076, a MET/AXL/FGFR inhibitor, in advanced solid tumors
2015 · S. Postel-Vinay, A. Hollebecque, et al. · Annals of Oncology · 2
Data from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
2023 · Sandra Dupouy, Ibtissam Marchiq, et al.
Supplementary Tables S1-S4 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
2023 · Sandra Dupouy, Ibtissam Marchiq, et al.
Supplementary Materials & Methods SM1 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
2023 · Sandra Dupouy, Ibtissam Marchiq, et al.
PDF
Supplementary Figures S1-S9 from Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
2023 · Sandra Dupouy, Ibtissam Marchiq, et al.
Works count: 12
Citation count: 703
H-index: 5
I10-index: 5
Year
Topic
Type